Blog | HemaCare

Nancy Andon, MSc


Recent Posts

The Changing Landscape of Clinical Approval

Aug 27, 2019 10:04:00 AM / by Nancy Andon, MSc posted in Gene Therapy, Cell Therapy, Drug Discovery

0 Comments

HemaCare is pleased to announce the publication of our latest article [1] in the journal International Clinical Trials (ICT). The paper, entitled “The Landscape of Clinical Approval” describes how changes in the clinical drug approval process are impacting starting material suppliers, and what suppliers are doing to meet increased demands.

Read More

Medicare’s Decision to Cover Cell Therapy Treatments

Aug 13, 2019 10:07:00 AM / by Nancy Andon, MSc posted in Cancer, CAR-T, Cell Therapy

0 Comments

A major breakthrough in Immunotherapy drug coverage was announced last week. Medicare will now cover high-priced blood cancer cell therapies nationwide. The news, announced by officials at the Centers for Medicare and Medicaid Services (CMS), comes two years after the FDA approved the first CAR-T therapy in 2017, Novartis’ Kymriah®, a treatment for acute lymphoblastic leukemia. This long sought-after coverage decision will now ensure patients have consistent and predictable access to potentially life-saving therapies.[1]   

Read More

PBMC Reprogramming Opens Doors in Regenerative Medicine

Aug 6, 2019 10:04:00 AM / by Nancy Andon, MSc posted in PBMCs, Regenerative Medicine, Stem Cells

0 Comments

New clinical applications in regenerative medicine are motivating an intense interest in easily accessible sources for producing human stem cells. The 2007 breakthrough showing that induced pluripotent stem cells (iPSC) could be generated directly from adult cells has been a boon to the industry. Since that time, there has been a steady refinement of the cell culture techniques that guide the cell reprogramming process.

Read More

Can TRuCs Beat CARs?

Jul 30, 2019 10:08:00 AM / by Nancy Andon, MSc posted in CAR-T, Immunotherapy, T Cells

0 Comments

Exciting new research published in Nature Communications cites using HemaCare leukapheresis material to design primary human T cells that may be more effective at fighting cancer than CAR-T cells. [1]

The successful treatment of B cell leukemias with genetically modified T cells heralded a new frontier in cell-based medicines. CAR-T cells, or chimeric antigen receptor T cells, have become the face of cell and gene therapy, with Novartis’ first-in-class Kymriah® prompting a robust pipeline of competitive CAR-T treatments. Now a research group in Cambridge, Massachusetts is taking T cell-based immunotherapy one step further. By changing the way T cells target cancer cells, they claim to have come up with a more effective cancer immunotherapy mechanism.

Read More

Mobilization Mechanics: The Complex World of Stem Cell Mobilization

Jul 24, 2019 10:11:00 AM / by Nancy Andon, MSc posted in Apheresis, Stem Cells

0 Comments

Stem cells are the foundation from which all other cells with specialized functions are generated. Stem cells are primarily found in the bone marrow, where they are produced, but can be induced to migrate into the peripheral blood circulation through a process known as mobilization.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts